Summary & Overview
CPT 81408: Advanced Molecular Pathology Laboratory Procedure
CPT code 81408 is a high-level molecular pathology procedure used in laboratory settings to analyze complex genetic and chromosomal anomalies. As a Tier 2, Level 9 code, it covers advanced molecular testing that plays a critical role in diagnosing rare genetic conditions and assessing susceptibility to certain diseases, including cancer and metabolic disorders. The code is widely recognized across major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting its importance in clinical diagnostics and laboratory medicine.
This publication provides a comprehensive overview of CPT 81408, including payer coverage, clinical context, and related billing practices. Readers will gain insights into the code's clinical applications, typical laboratory settings, and its relationship to other molecular pathology codes. The summary also highlights relevant modifiers and associated taxonomies, offering a clear understanding of how this code fits within broader molecular genetic testing workflows. Policy updates and benchmarks are discussed to inform stakeholders about current trends and requirements in molecular pathology billing and reimbursement.
CPT Code Overview
CPT 81408 represents Tier 2 Molecular Pathology Procedures, Level 9. This code is used for advanced molecular laboratory testing, typically performed in specialized laboratory settings. The service type is Molecular Pathology / Laboratory, and the typical site of service is Laboratory (POS 81). These procedures are essential for identifying genetic and chromosomal anomalies, supporting clinical decision-making in complex cases.
Clinical & Coding Specifications
Clinical Context
A patient is referred for advanced molecular genetic testing due to suspicion of a rare genetic disorder, unexplained metabolic abnormalities, or screening for genetic susceptibility to cancer. The ordering provider may be a specialist in medical genetics, pathology, or internal medicine. The specimen is collected and sent to a laboratory (Place of Service 81), where Tier 2 molecular pathology procedures at Level 9 are performed. The laboratory analyzes the genetic material to identify mutations or chromosomal anomalies, which assists in diagnosis, prognosis, or management of the patient's condition. Results are interpreted by a molecular genetic pathologist and reported back to the ordering provider.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component (interpretation of results) of the laboratory service. - Modifier
TC: Used when reporting only the technical component (performance of the test) of the laboratory service. - Modifier
91: Used when the laboratory test is repeated on the same patient for clinical reasons.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207ZP0213X | Pathology - Molecular Genetic Pathology |
207L00000X | Anatomic Pathology |
207RI0200X | Internal Medicine - Medical Genetics |
Related Diagnoses
-
Z13.79- Encounter for other screening for genetic and chromosomal anomalies- Relevant for patients undergoing genetic screening without a specific diagnosis, often as part of preventive care or risk assessment.
-
Q85.9- Phakomatosis, unspecified- Applies to patients with suspected or confirmed phakomatosis, a group of genetic disorders affecting multiple organ systems.
-
C80.1- Malignant (primary) neoplasm, unspecified- Used when a patient has a primary malignant neoplasm of unknown origin, and molecular testing may help identify genetic mutations associated with cancer.
-
Z15.09- Genetic susceptibility to other malignant neoplasm- Indicates patients with a known genetic predisposition to cancer, warranting molecular pathology procedures to assess risk or guide management.
-
E88.89- Other specified metabolic disorders- Relevant for patients with metabolic disorders of unclear etiology, where genetic testing may assist in diagnosis or management.
Related CPT Codes
-
81406- Tier 2 Molecular Pathology Procedures, Level 7- Used for molecular pathology procedures of moderate complexity; may be performed in similar clinical scenarios but for different genetic targets.
-
81407- Tier 2 Molecular Pathology Procedures, Level 8- Represents a higher complexity than
81406, but less than81408; may be used as an alternative or in conjunction with81408depending on the genetic analysis required.
- Represents a higher complexity than
-
81216- BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis- Specifically used for BRCA2 gene sequencing; may be ordered alongside
81408if comprehensive genetic testing is needed for cancer susceptibility.
- Specifically used for BRCA2 gene sequencing; may be ordered alongside
These codes are commonly used together in workflows involving comprehensive genetic testing or as alternatives based on the specific genetic targets and complexity required.
National Reimbursement Benchmarks
National mean rates for CPT code 81408 among commercial payers are notably higher than typical Medicare rates, with the BUCA (average commercial) mean rate at $1,522.31. Blue Cross Blue Shield and Cigna both report mean rates above $1,600, while Aetna's mean rate is the lowest among the major commercial payers at $1,340.65.
Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $1,747.83 between its 75th and 25th percentiles, indicating substantial variability in reimbursement. In contrast, Aetna and UnitedHealth Group show tighter ranges, with dispersions of $776.00 and $920.00, respectively. Blue Cross Blue Shield and BUCA also display moderate spreads, suggesting some variability but less than Cigna.
The table and chart below present a detailed breakdown of national mean rates and percentile distributions for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.